Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cyclopropanecarboxamide derivative F crystal form and preparation method thereof

A technology of cyclopropane carboxamide and derivatives, which is applied in organic chemical methods, drug combinations, pharmaceutical formulations, etc., can solve problems such as unfavorable hygroscopicity and instability of cyclopropane carboxamide derivatives, and achieve excellent high temperature stability, good bioavailability effect

Active Publication Date: 2015-12-30
SHANGHAI SUNTRONG BIOTECH
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The problem to be solved by the present invention is that problems such as instability, hygroscopicity and easy conversion into stable crystal forms of existing cyclopropanecarboxamide derivatives are unfavorable for pharmaceutical processing and use in pharmaceutical compositions. Cyclopropanecarboxamide derivatives The problem of providing more qualitative and quantitative information for the curative effect research of solid drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cyclopropanecarboxamide derivative F crystal form and preparation method thereof
  • Cyclopropanecarboxamide derivative F crystal form and preparation method thereof
  • Cyclopropanecarboxamide derivative F crystal form and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Embodiment 1 Preparation of cyclopropanecarboxamide derivative F crystal form

[0036] Weigh 500 mg of the cyclopropanecarboxamide derivative raw material into a container, add it to 100 mL of water (analytical grade), suspend at 35°C for 48 hours, filter, and vacuum-dry to obtain an off-white powder. Its yield of weighing calculation is 53%.

Embodiment 2

[0037] Embodiment 2 Preparation of cyclopropanecarboxamide derivative F crystal form

[0038] Weigh 500mg of cyclopropanecarboxamide derivative raw material in a container, add 30mL N,N-dimethylformamide (analytical grade) to dissolve it completely, add the resulting solution to 50mL water (analytical grade), there is a white solid Precipitate, stand at room temperature for 12 hours, filter, vacuum dry to obtain off-white powder. Its yield of weighing calculation is 56%.

Embodiment 3

[0039] Embodiment 3. characterize cyclopropanecarboxamide derivative F crystal form by XRPD pattern

[0040]The measurement of the X-ray powder diffraction (XRPD) pattern is carried out using the RigakuUltimaIV model combined multifunctional X-ray diffractometer, and the specific collection information is as follows: Cu anode (40kV, 40mA), scanning speed 20° / min, scanning range (2θ range) 3~45°, scan step size 0.02, slit width 0.01. Samples were processed using glass slides pressed directly onto the test plate. Subsequent XRPD patterns all adopt similar measurement methods.

[0041] Determination of the XRPD spectrum of the cyclopropanecarboxamide derivative F crystal form prepared according to the method described in Example 1, at 2θ=7.621, 8.879, 11.061, 11.44, 14.061, 15.316, 16.08, 16.539, 17.281, 18.142, 19.859, 20.938, There are diffraction peaks at 22.299, 23.04, 23.96, 24.62, 25.121, 26.619, 28.2, and 28.86, such as figure 1 shown. The error range of 2θ value is ±0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a cyclopropanecarboxamide derivative F crystal form (please see the specification for the formula) in the formula (I). According to the XRPD illustration of the crystal form, diffraction peaks exist when 2Q is equal to 8.717, 9.758, 10.299, 10.8, 12.879, 15.401, 16.64, 16.92, 17.859, 18.759, 19.499, 20.678, 22.841, 23.178, 23.88, 24.479, 25.958, 27.06, 28.039, 29.521 and 31.121, and the error range of the 2Q value is + / -0.2. The cyclopropanecarboxamide derivative F crystal form has good high-temperature stability, high-humidity stability and illumination stability. Moreover, low moisture absorption performance is achieved. The cyclopropanecarboxamide derivative F crystal form can be applied to drugs for treatment or prevention of JAK-participated inflammation and autoimmunity diseases, proliferative diseases, graft rejective reactions and congenital cartilage deformation or diseases caused by IL6 oversecretion, and good bioavailability is achieved. Meanwhile, qualitative and quantitative information is provided, which is of important significance to further studying the curative effect of the solid drugs.

Description

technical field [0001] The present invention relates to a polymorphic form of a cyclopropanecarboxamide derivative as a JAK inhibitor, in particular to a crystal form F of a cyclopropanecarboxamide derivative and a preparation method thereof. Background technique [0002] JAK is Janus Kinase, which is a non-receptor tyrosine protein kinase and a non-transmembrane tyrosine kinase. This is because JAK can not only phosphorylate the cytokine receptors associated with it, but also phosphorylate multiple signaling molecules containing specific SH2 domains. The JAK protein family includes 4 members: JAK1, JAK2, JAK3 and TYK2, which have 7 JAK homology domains (JAKhomology domain, JH) in their structure, of which the JH1 domain is the kinase domain and the JH2 domain is the "false" The kinase domain, JH6 and JH7 are receptor binding domains. [0003] TYK2 is a potential target for immunoinflammatory diseases, which has been confirmed by human genetics and mouse knockout studies (...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D471/04A61K31/541A61P37/02A61P29/00A61P35/00A61P37/06A61P19/08
CPCC07B2200/13C07D471/04
Inventor 弋东旭陈金瑶于迎渌
Owner SHANGHAI SUNTRONG BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com